Physician profile
James D Saar
NPI 1235104902
$3,397.34
in general payments reported to CMS, 2019-2025
16 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,770 · 2021: $68.05 · 2022: $198 · 2023: $429 · 2024: $718 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $920.25 | 2019-2024 | 1788 |
| Mentor Worldwide LLC | $719.65 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander, Mentor Cpx 2 Breast Tissue Expander |
| Medical Device Business Services, INC. | $514.55 | 2019 | |
| Kerecis Limited | $435.94 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Galderma Laboratories, L.P. | $169.41 | 2019-2025 | Dysport |
| Acera Surgical, INC. | $134.14 | 2023 | Restrata Wound Matrix |
| Abbvie INC. | $119.64 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| E.R. Squibb & Sons, L.L.C. | $112.00 | 2019 | |
| Allergan, INC. | $81.90 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $52.36 | 2021-2024 | Exparel |
| Vertex Pharmaceuticals Incorporated | $47.06 | 2025 | |
| Kci USA, INC. | $20.90 | 2019 | |
| Next Science LLC | $20.66 | 2022 | |
| Bard Peripheral Vascular, INC. | $18.53 | 2021 | |
| Wright Medical Technology, INC. | $15.67 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aclaris Therapeutics, INC. | $14.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Saar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.